Major Milestones in Valve Replacement Technology
Laplace Interventional has celebrated two significant achievements recently. The company has completed patient enrollment in its US Early Feasibility Study (EFS) focused on its innovative Trans-jugular (TJ) system and has treated its first two patients using the new Trans-femoral (TF) delivery system. These milestones illustrate Laplace's commitment to enhancing patient care in the field of heart valve replacement.
Successful Enrollment in US Early Feasibility Study
Based in Minnesota, Laplace Interventional, a pioneering medical device company, has successfully enrolled a total of 41 patients in its EFS for the TJ system. Among these, 37 patients are in the US, while others are in locations such as Canada and the Republic of Georgia. The promising results of this feasibility study will be shared by Dr. Kashish Goel, an esteemed Interventional Cardiologist from Vanderbilt University Medical Center, at an upcoming conference, highlighting the advancements made with this new technology.
Presenting Innovative Results
At the Transcatheter Cardiovascular Therapeutics (TCT) conference, Dr. Goel is set to present the results under the title "The Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System: EFS Update." This presentation will provide insights into the advancements and positive outcomes observed during the study, aiming to shed light on the potential of Laplace's device in treating Tricuspid Regurgitation (TR).
Introduction of the Trans-Femoral Delivery System
In addition to the ongoing study, Laplace has also introduced a Trans-femoral (TF) delivery system which utilizes the same valve prosthesis as in the TJ approach. The first two successful procedures utilizing this method were conducted by Dr. Irakli Gogorishvili and Dr. Gvantsa Dughashvili at Healthycore in Tbilisi, Republic of Georgia. The procedures were supported by prominent structural heart specialists from the US, showcasing a collaborative effort in advancing cardiac care.
Enhancing Patient Care Worldwide
Laplace Interventional aims to significantly enhance the quality of life for patients diagnosed with Tricuspid Regurgitation globally. The innovative prosthetic valve is designed to be delivered through minimally invasive methods, either through a neck or groin vein, which is anticipated to reduce potential complications compared to traditional valve replacement surgeries.
Expert Feedback and Insights
Dr. Goel shared his thoughts on the device, stating, "Our experience with the Laplace valve utilizing the TJ method has been extremely positive during the EFS, with several patients having follow-ups exceeding one year. The innovative design of Laplace enables treatment for a diverse range of patient anatomies, including those that may be unsuitable for other TTVR devices. The successful completion of the initial two TF cases further broadens the capability of the device, catering to patient preferences for access methods.”
Company's Vision and Commitment
Founder and CEO Ramji Iyer, PhD, expressed pride in these achievements, stating, "The completion of the US EFS with the TJ approach and the successful TF cases are significant milestones for our company. I would like to extend my gratitude to all the clinical investigators and their teams for their dedication to excellent patient care. We appreciate Dr. Goel, Dr. Safi, Dr. Gogorishvili, and Dr. Dughashvili for their exemplary work in completing the TF cases with outstanding results. We are excited to share our clinical experiences and future plans for the Laplace TTVR system at TCT next week."
Future Prospects
Laplace Interventional's device technology is still in the development phase and has yet to receive approval from the FDA or other regulatory bodies across global markets. The company remains focused on gathering further clinical data to enhance its offerings and provide effective solutions for patients suffering from heart valve-related issues.
Frequently Asked Questions
What is the main purpose of Laplace Interventional's device?
The device aims to improve the treatment of Tricuspid Regurgitation (TR) through a minimally invasive procedure.
How many patients were involved in the Early Feasibility Study?
Forty-one patients were enrolled in the Early Feasibility Study covering the Trans-jugular system.
Who presented the results of the feasibility study?
Dr. Kashish Goel presented the results on behalf of the study investigators at a major conference.
Where were the first two Trans-femoral procedures conducted?
The procedures were successfully performed in Tbilisi, Republic of Georgia by qualified doctors at Healthycore.
What future events is Laplace Interventional participating in?
Laplace Interventional is expected to share their clinical experiences and future plans at the upcoming Transcatheter Cardiovascular Therapeutics conference.
